Literature DB >> 11592527

Animal and culture models of glaucoma for studying neuroprotection.

L A Levin1.   

Abstract

PURPOSE: Neuroprotection aims to treat nervous system disease by maintaining the health and function of neurons. The final proof of the neuroprotective strategy relies on randomized, controlled clinical trials, but the choice of which agents to study for these trials depends on studies in the laboratory using culture and animal models. Most culture models for studying ocular neuroprotection use retinal cells, and a range of mechanisms can be studied in culture, e.g. axotomy and serum or growth factor deprivation.
METHODS: A variety of animal models are available for studying neuroprotection as possible therapy for glaucomatous optic neuropathy. Those most closely related to glaucoma are probably associated with moderate elevation of the intraocular pressure to levels similar to those seen in patients with untreated glaucomatous optic neuropathy.
CONCLUSIONS: Care should be taken when applying the results of these models to humans, and there is no single criterion for deciding which culture or animal model is most relevant to the clinical situation. The most important feature is whether the model's results correlate with clinical results, and this information will only become available over time, as randomized clinical trials are completed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592527     DOI: 10.1177/112067210101102s02

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  3 in total

Review 1.  In Vitro Cell Models for Ophthalmic Drug Development Applications.

Authors:  Sara Shafaie; Victoria Hutter; Michael T Cook; Marc B Brown; David Y S Chau
Journal:  Biores Open Access       Date:  2016-04-01

2.  Both systemic and local application of granulocyte-colony stimulating factor (G-CSF) is neuroprotective after retinal ganglion cell axotomy.

Authors:  Tobias Frank; Johannes C M Schlachetzki; Bettina Göricke; Katrin Meuer; Gundula Rohde; Gunnar P H Dietz; Mathias Bähr; Armin Schneider; Jochen H Weishaupt
Journal:  BMC Neurosci       Date:  2009-05-14       Impact factor: 3.288

3.  Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage.

Authors:  Richard T Libby; Yan Li; Olga V Savinova; Joseph Barter; Richard S Smith; Robert W Nickells; Simon W M John
Journal:  PLoS Genet       Date:  2005-07-25       Impact factor: 5.917

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.